Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma: A Randomized Phase 2 Investigator-Initiated Trial

NCT07699939 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT07699939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07699939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma: A Randomized Phase 2 Investigator-Initiated Trial
Lead sponsor
National Cancer Center, Japan
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2026
Completion date
June 30, 2029
Enrollment
136 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction (gej) adenocarcinoma